RxDoctor Payments Data

Avinash Gupta, MD

Cardiovascular Disease · Lakewood, NJNPI 1265531487

Payments from drug & device makers

$49,578in general payments, 2019–2025

Across 973 payments — averaging $50.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$25K
  • Johnson & Johnson$9K
  • Cvrx, Inc.$2K
  • Boston Scientific$2K
  • Novartis$1K
  • Amgen$1K
  • plus $9K from 41 others

What the payments were for

  • Speaking & faculty fees$29,21059%
  • Travel & lodging$4,3599%
  • Food & beverage$15,75732%
  • Education$2521%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,578 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$533,280
Medicare patients
1,437
Services billed
6,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban413$542,952
EntrestoSacubitril/Valsartan139$228,915
XareltoRivaroxaban137$167,077
BrilintaTicagrelor102$109,592
Repatha SureclickEvolocumab64$90,267
FarxigaDapagliflozin Propanediol66$70,853
JardianceEmpagliflozin35$39,145
VascepaIcosapent Ethyl46$32,877
OzempicSemaglutide25$32,016
Icosapent Ethyl50$30,057
JanumetSitagliptin Phos/Metformin Hcl22$20,023
JanuviaSitagliptin Phosphate12$18,812
Ezetimibe450$13,343
Praluent PenAlirocumab11$12,960
Rosuvastatin Calcium799$12,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$778$542,952413 claims
NovartisEntresto$1,434$228,915139 claims
AstraZenecaBrilinta, Farxiga$1,064$180,444168 claims
Johnson & JohnsonXarelto$9,314$167,077137 claims
Boehringer IngelheimJardiance$721$39,14535 claims
MerckJanumet, Januvia$440$38,83534 claims
Novo NordiskOzempic$613$32,01625 claims
Lilly USA, LLCMounjaro$15$10,80611 claims
Astellas Pharma US IncMyrbetriq$220$6,75513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Lakewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →